Improving treatments and quality of life for
blood cancer patients
As the largest nonprofit funder of blood cancer research in the world, Blood Cancer United has been instrumental in the development of nearly every breakthrough in blood cancer treatment. Because of Blood Cancer United, blood cancers that were once fatal are now treatable—and even curable.
Donor-supported Blood Cancer United funding plays a pivotal role in advancing treatments that exponentially improve survival rates and quality of life for patients with many types of blood cancer. Still, there is much more for us to accomplish.
See how research funded by Blood Cancer United has fueled more effective therapies, read about prominent projects from our current portfolio, and get to know the research priorities that will help us find a possible cure for blood cancers.
In 2022 alone, Blood Cancer United research grants and support from the Therapy Acceleration Program® (TAP) supported over 220 scientists at the world’s most prestigious institutions.
Research investment:
$233.8 MILLION
Total multi-year funding in research
$62M
AML
26.5%
$44M
Aggresive
NHL
18.6%
$32M
Myeloma
13.5%
$26M
MDS/MPNS
11.2%
$19M
General
Lymphoma
7.9%
$16M
Indolent
NHL
6.9%
$14M
ALL
6.1%
$10M
General
Leukemia
4.4%
$5M
CLL/SLL
2.2%
$5M
Hodgkin
Lymphoma
2.1%
Any discrepancies are due to rounding; total investment=$233.8M.
Our impact across blood cancer types
Nearly every breakthrough in blood cancer treatment has emerged from our support of leukemia research, from chemotherapy to groundbreaking CAR T-cell immunotherapy. With more than $78 million committed to leukemia research, we are leading the way to cures.
Learn moreOur investment in lymphoma research has led to significant advances, such as rituximab (Rituxan®) and innovative immunotherapy, including the first chimeric antigen receptor (CAR) T-cell-therapy approved by the FDA for lymphoma patients, axicabtagene ciloleucel (Yescarta®). Our current lymphoma research commitment exceeds $89 million, so we can continue to bring promising new treatments to patients.
Learn moreMultiple myeloma (MM) made up close to 20% of all new blood cancer cases diagnosed in the US in 2019. This disease is characterized by the uncontrolled proliferation of abnormal monoclonal plasma cells in the bone marrow. As these abnormal cells grow in excess, they disrupt normal cell production, which can result in a range of complications, particularly in the bones, blood, kidney and immune system. People with multiple myeloma develop tumors in more than one location inside and sometimes outside of the bone marrow, hence the name "multiple" myeloma.
Learn moreWe are supporting advanced genomics and molecular research to understand the causes of MDS and improve diagnosis and treatment. Blood Cancer United is funding over 30 active grants in MDS research worldwide.
Learn moreBlood Cancer United is collaborating with the MPN Research Foundation to develop therapies for polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis (MF)—the group of blood cancers collectively known as myeloproliferative neoplasms.
Learn moreWe award funds for studies that range from basic blood cancer research to clinical trials.
For nearly seventy-five years, Blood Cancer United support has been instrumental in developing most breakthroughs in blood cancer treatment.
Blood cancer research grants
Our research grant portfolio contains programs that cover blood cancer research from the earliest phase of discovery science to translational research. Providing support to today's promising early-career scientists is fundamental to making sure that they will continue contributing to blood cancer research as tomorrow's leaders in the field.
Therapy Acceleration Program® (TAP)
TAP is a mission-driven, strategic venture philanthropy initiative that seeks to accelerate the development of innovative blood cancer therapeutics and change the standard of care, while also generating a return on investment for the Blood Cancer United mission. TAP collaborates with biotech companies to support the development of novel platforms, first-in-class assets addressing high unmet medical needs, emerging patient populations, and orphan indications.
